Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma

INTRODUCTION: Hepatocellular carcinoma (HCC) patients at advanced stages receive immunotherapy or treatment with tyrosine kinase inhibitors (TKIs) such as Sorafenib (Sora) or Lenvatinib in frontline as well as Regorafenib (Rego) or Cabozantinib in second-line. A major hindrance of TKI therapies is t...

Descripción completa

Detalles Bibliográficos
Autores principales: Breitenecker, Kristina, Hedrich, Viola, Pupp, Franziska, Chen, Doris, Řezníčková, Eva, Ortmayr, Gregor, Huber, Heidemarie, Weber, Gerhard, Balcar, Lorenz, Pinter, Matthias, Mikulits, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514905/
https://www.ncbi.nlm.nih.gov/pubmed/37746265
http://dx.doi.org/10.3389/fonc.2023.1238883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514905/
https://www.ncbi.nlm.nih.gov/pubmed/37746265
http://dx.doi.org/10.3389/fonc.2023.1238883

Ejemplares similares